Last updated on January 2020

A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)


Brief description of study

The primary objective of this study is to determine the efficacy of CaPre 4 g daily, compared to placebo, in lowering fasting TG levels in subjects with fasting TG levels 500 mg/dL and 1500 mg/dL (5.7 mmol/L and 17.0 mmol/L) after 12 weeks of treatment.

Approximately 615 subjects will be screened to obtain 245 randomized subjects following a treatment allocation ratio of 2.5:1 (CaPre:placebo).

Clinical Study Identifier: NCT03361501

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.